|Day Low/High||170.96 / 174.13|
|52 Wk Low/High||133.64 / 184.21|
The main headwind for Regeneron is that Swiss pharma giant Novartis could soon be a rival to the eye drug that drives most of Regeneron's revenue.
The main thrust of the order appears to be easing regulatory hurdles to drug approvals, which could lower the cost of bringing new treatments to market and thus lower prices.
Slowing sales and safety concerns have some investors less than enthused, but Amgen says it's drugs in development could deliver.
Oral Presentation of Phase 3 Data Shows KYPROLIS® (Carfilzomib) and Dexamethasone Improved Median Overall Survival by 7.6 Months Compared to Velcade® (Bortezomib) and Dexamethasone in Relapsed Multiple Myeloma
FDA Sets PDUFA Target Action Date of Feb. 3, 2018
Newly released neurotransmitter research could open up a $8 - $10 billion market as early as next year.
Data From Broad Clinical Program Show Investigational Erenumab is Effective at Preventing Migraine in Patients Experiencing Four or More Migraine Days a Month
The stock is set up well for more upside and remains very near a low-risk buy zone.
The day before Amgen appeared in court, the biopharma giant announced a submission to change its label on powerhouse drug Repatha.
Applications Based on Data From Repatha Cardiovascular Outcomes Study Showing an Additional Reduction in Heart Attacks, Strokes and Coronary Revascularizations on Top of Optimized Statin Therapy
Analysis Demonstrated XGEVA had a Significantly Lower Rate of Renal Adverse Events Compared to Zoledronic Acid
First Randomized Study to Evaluate the Combination of IMLYGIC, an Oncolytic Viral Therapy, With a Checkpoint Inhibitor
Massachusetts Governor Charles Baker and U.S. Senator Edward Markey Join Members of the Life Sciences Community at Newly Expanded Facility in Kendall Square
The tactic is the bearishly biased, calendar diagonal call spread, which controls the risk of the trade.
Amgen's osteoporosis setback will likely be seen as providing a commercial boost to Radius Health, which secured U.S. approval in April for a competing osteoporosis drug, Tymlos.
Radius Health, Amgen and Paratek Pharmaceuticals were among the biotech movers in premarket trading on Monday.
Wake Up Wall Street: Political Upheaval Surrounding President Trump Shows No Sign of Abating
UCB stock plummeted Monday after clinical trials shone a light over a possible safety risk related to the Osteoporosis treatment that it has been developing alongside Amgen
ARCH Study Met Primary and Key Secondary Endpoints by Reducing the Incidence of New Vertebral, Clinical and Non-Vertebral Fractures
New Analysis From Cardiovascular Outcomes Trial Shows Addition of Repatha in Patients Considered at Goal Further Reduces Cardiovascular Event Risk